Aquestive Therapeutics, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2021-03-12

Reporting Person: Cochran John (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-12	Common Stock	J	23038	—	Acquired	98123	Direct
2021-03-12	Common Stock	J	8228	—	Acquired	106351	Direct
2021-03-12	Common Stock	J	11544	—	Acquired	117895	Direct
2021-03-12	Common Stock	J	19091	—	Acquired	136986	Direct

Footnotes

F1: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities.